User profiles for R. Stone
Robert StoneProfessor, School of Mechanical, Industrial and Manufacturing Engineering, Oregon State … Verified email at oregonstate.edu Cited by 30646 |
The BABAR detector
…, A Romosan, MT Ronan, VG Shelkov, R Stone… - Nuclear Instruments and …, 2002 - Elsevier
BABAR, the detector for the SLAC PEP-II asymmetric e + e − B Factory operating at the ϒ(4S)
resonance, was designed to allow comprehensive studies of CP-violation in B-meson …
resonance, was designed to allow comprehensive studies of CP-violation in B-meson …
Evidence and implications of recent climate change in northern Alaska and other arctic regions
…, CH Racine, VE Romanovsky, RS Stone… - Climatic change, 2005 - Springer
The Arctic climate is changing. Permafrost is warming, hydrological processes are changing
and biological and social systems are also evolving in response to these changing …
and biological and social systems are also evolving in response to these changing …
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
…, BJ Djulbegovic, M Wadleigh, DJ DeAngelo, RM Stone… - Jama, 2009 - jamanetwork.com
Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1)
is uncertain. Current consensus, based on cytogenetic risk, recommends …
is uncertain. Current consensus, based on cytogenetic risk, recommends …
The sloan digital sky survey: Technical summary
The Sloan Digital Sky Survey (SDSS) will provide the data to support detailed investigations
of the distribution of luminous and nonluminous matter in the universe: a photometrically …
of the distribution of luminous and nonluminous matter in the universe: a photometrically …
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
…, J Sierra, WA Stock, RM Stone… - Blood, The Journal …, 2022 - ashpublications.org
The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …
within a collaboration between the World Health Organization (WHO), the Society for …
[HTML][HTML] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
…, RT Silver, JM Goldman, RM Stone… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
[BOOK][B] The linear complementarity problem
RW Cottle, JS Pang, RE Stone - 2009 - SIAM
The first edition of this book was published by Academic Press in 1992 as a volume in the
series Computer Science and Scientific Computing edited by Werner Rheinboldt. As the most …
series Computer Science and Scientific Computing edited by Werner Rheinboldt. As the most …
The usno-b catalog
…, AR Rhodes, B Riepe, S Sell, RC Stone… - The Astronomical …, 2003 - iopscience.iop.org
USNO-B is an all-sky catalog that presents positions, proper motions, magnitudes in various
optical passbands, and star/galaxy estimators for 1,042,618,261 objects derived from …
optical passbands, and star/galaxy estimators for 1,042,618,261 objects derived from …
[HTML][HTML] A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
…, P Marynen, SE Coutre, R Stone… - … England Journal of …, 2003 - Mass Medical Soc
Background Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia
associated with organ dysfunction. It is of unknown cause. Recent reports of responses to …
associated with organ dysfunction. It is of unknown cause. Recent reports of responses to …
[HTML][HTML] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an …